Panel endorses Merck's anti-clotting drug

Share this article:

Advising the FDA to “do its due diligence” about bleeding risk, an FDA panel voted 10-1 in favor of Merck's anti-clotting drug vorapaxar, which would have the brand name Zontivity, Reuters reports. The panel and Merck want to limit the drug's use to heart attack patients without a stroke history, because of an increased bleeding risk among stroke patients.

Aspirin, and Bristol-Myers Squibb's now off-patent Plavix (clopidogrel) seek the same goal—to prevent clots—but Reuters notes Merck's potential market peer works differently, by inhibiting a PAR-1 receptor.

The panel also says the drug should come with a weight minimum because lighter patients appear to be at a higher risk for bleeds.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.